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Febrile Neutropenia
Tonja Plew, BSN, RN, OCN
• Febrile Neutropenia (FN) is a potentially life-threatening 
oncologic emergency, which requires immediate and 
aggressive treatment with broad-spectrum antibiotics. 
(Bossaer & Cluck, 2013)
• FN occurs when a patient has a temperature of greater than 
100.4˚F with an Absolute Neutrophil Count (ANC) of less than 
500 cells/mm³, often with fever being the only sign of 
infection (Bossaer & Cluck, 2013)
• In cancer patients, FN is a common cause of morbidity and 
mortality, and results in high medical costs. (Flowers et al., 
2013)
• Approximately 60,000 patients are admitted for FN annually. 
(Bennett, Djulbegovic, Norris, & Armitage, 2013)
Otterbein University, Westerville, Ohio
▪ Hematologic cancers comprise several different cancers, such as leukemia, lymphoma, 
and multiple myeloma, and affect the blood, bone marrow, and lymphatic systems, 
which increases susceptibility to infection. (Bryant et al., 2014)
▪ Neutrophils are the most common type of white blood cell in the bloodstream. A key 
part of the immune system, they are early responders to pathogen invasion and ingest 
bacteria through phagocytosis. (Bennett et al., 2013)
▪ Treatment of these cancers with myelosuppressive chemotherapy affects all rapid 
cycling cells. While chemotherapy targets rapid cycling cancer cells, normal rapid 
cycling cells within the gastrointestinal (GI) tract and bone marrow are negatively 
affected. (Bennett et al., 2013)
▪ Rapid cycling hematopoietic cells of the bone marrow undergo immediate and 
cumulative damage, resulting in neutropenia.  (Bennett et al., 2013)
▪ Neutropenia may result from bone marrow injury due to the cancer directly, 
chemotherapy and radiation, other underlying diseases, or a combination of all events, 
further increasing susceptibility to infection. (Lucas et al., 2018)
▪ Rapid cycling cells within the mucosal linings of the gastrointestinal (GI) tract provide 
natural defenses against pathogens. Mucosal barrier injury from chemotherapy or 
radiation leads to mucositis, allowing bacteria from the GI tract to seed in the 
bloodstream, causing a sustained inflammatory response with fever. Bacteria from the 
altered GI tract are often responsible for infections in FN. (Lucas et al. 2018)
▪ When chemotherapy-induced neutropenia develops, endogenous cytokines are 
released by epithelial cells and may result in fever even in the absence of infection. 
(Bennett et al., 2013)
▪ Microorganism access through central lines, may lead to microbial invasion in the  
immunocompromised cancer patient  (Lucas et al., 2018)
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▪ As an oncology nurse at The Ohio State University’s James 
Cancer Hospital, I chose the topic of FN as many of our 
patients receiving chemotherapy experience this complication 
at some point during their treatment, and nurses play a vital 
role in both prevention and early recognition of FN. 
▪ Temperature is used to screen patients who are receiving 
chemotherapy for infection. (Niven et al., 2014)
▪ Fever is defined as a temperature of 100.4˚F or higher, and may 
be the earliest and only sign in FN. (Niven et al., 2014)
▪ Due to neutropenia, cardinal signs and symptoms of infection 
such as redness, warmth, and swelling may not be present. 
(Lucas, Olin, & Coleman, 2018)
▪ With severe infection, patients may present with signs of sepsis, 
such as hypotension and tachycardia. (Bryant et al., 2014)
▪ In many cases of FN, the infectious etiology will not be 
determined, with only approximately 30% of cases documented 
with infections. (Lucas et al., 2018)
▪ Length and severity of neutropenia are two important factors. An 
ANC below 500 is considered severely neutropenic, 500-1000 is 
moderate,1000-1500 is minimal, and greater than 1500 is not 
clinically significant. (Bryant et al., 2014). 
▪ The ANC is calculated by multiplying the total white blood cell 
count by the percentage of polymorphonuclear cells and bands. 
(Bryant et al., 2014)
▪ The Multinational Association for Supportive Care in Cancer 
Score (MASSC)  is used to calculate whether a patient with FN is 
high risk (score >21) or low risk (score <21). All high risk patients 
must be treated in the inpatient setting. (Bergstrom, Magalla, & 
Gupta, 2018)
▪ Nurses play an important role in educating patients, families, and 
caregivers of infection prevention strategies, as well as the signs 
and symptoms of infection, with clear instructions of when and 
how to contact healthcare providers. (Flowers et al., 2013)
▪ The Oncology Nursing Society recommends protective 
precautions such as hand hygiene, avoiding visitors with 
respiratory illnesses, drinking filtered water and ice, avoiding live 
plants, and avoiding animal feces to decrease exposure to 
infectious organisms while neutropenic. (Bryant et al., 2014)
▪ Neutropenia following myelosuppressive chemotherapy typically 
lasts 6-8 days, which is the most critical timeframe to avoid 
potentially infectious exposure. (Bennett et al., 2013)
▪ Patients receiving chemotherapy should be instructed to monitor 
temperatures twice daily, and report any value over 100.4˚F  
immediately. (Bryant et al., 2014)
▪ Use of rectal thermometers is contraindicated in the neutropenic 
patient due to infection risk from the altered GI tract. (Niven et al., 
2014)
▪ In the ED setting, nurses should be aware that FN is a potentially 
life-threatening, oncologic emergency, thus these patients should 
receive “fast tracking” to avoid delays in treatment. (Keng et al., 
2015)
▪ Broad spectrum antibiotics should be initiated within one hour of 
documented fever, if possible. (Flowers et al., 2013)
▪ FN is mainly treated in the inpatient setting, but low risk patients 
may receive more outpatient management in the future to contain 
costs. (Flowers et al., 2013)
▪ GCSF is an effective, yet very costly medication used to decrease 
the duration and intensity of neutropenia.(Bennett et al., 2013)
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• Neutropenia is a common side effect of chemotherapy, which 
leads to increased risk for infections.(Weycker, Barron, 
Kartashov, Legg, & Lyman, 2014)
• Most standard-dose myelosuppressive chemotherapy is 
associated with 6-8 days of neutropenia, with the lowest point 
of neutropenia known as the nadir. (Bennett et al., 2013)
• The absolute neutrophil count (ANC) is the lab value 
monitored to assess the degree of neutropenia, and provides 
an estimate of a patient’s ability to fight off infection. (Weycker
et al., 2014)
• For patients receiving myelosuppressive chemotherapy, a 
complete blood count with differential is monitored twice 
weekly to assess the ANC. (Weycker et al., 2014)
• While central lines are essential for administration of many 
chemotherapies, they are a significant risk factor responsible 
for at least 400,000 blood stream infections in cancer patients 
per year in the U.S. (Raad & Chaftari, 2014)
• In FN, empirical treatment with broad-spectrum antibiotics is 
recommended within one hour of a documented fever, even 
without a confirmed infection to avoid sepsis, and potentially, 
death. (Bennett et al., 2013)
• Antibiotics are continued while the infectious work up is in 
progress with blood cultures, chest X-ray, and possibly urine, 
stool, or sputum cultures. (Bryant, Walton, & Albrecht, 2014). 
Significance of Pathophysiology
Presentation of Process
▪ Neutropenia in cancer patients results in a high risk of infections, many of which are 
bacterial, but may also be fungal or viral. (Bryant et al., 2014)
▪ Patients with cancer are at high risk for gram negative-infections, such as Escherichia 
coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Stenotrophomonas maltophiliadue, due to neutropenia, lymphocyte dysfunction, 
mucositis, and use of central lines. (Perez, Adachi, & Bononmo, 2014)
▪ Coagulase-negative staphylococci are currently the most common pathogen identified 
in blood cultures. (Flowers et al., 2013)
▪ Gram-positive organisms are also leading causes of serious infection in cancer 
patients with neutropenia, including Staphylococcus aureas, Streptococcus 
pneumoniae, and Enterococcus faecalis. (Raad & Chaftari, 2014)
▪ Viral and fungal infections are less common, but patients are treated empirically with 
acyclovir and fluconazole to prevent viral and fungal illnesses when severe 
neutropenia is expected. (Bryant et al., 2014)
▪ Granulocyte colony-stimulating factors (GCSF), typically filgrastim or pegfilgrastim, are 
subcutaneous injections used prophylactically to minimize the risk of FN by shortening 
the duration and severity of neutropenia. Injections are initiated 24-72 hours after 
completion of chemotherapy. (Bennett et al, 2013)
▪ FN is a potentially life-threatening, oncologic emergency which 
requires immediate attention and aggressive management. 
Bossaer & Cluck, 2013)
▪ Broad spectrum antibiotics should be initiated within one hour of 
documented fever, if possible, even if infection cannot be 
confirmed. (Bennett, et al., 2013)
▪ Hand hygiene is the single most effective measure in preventing 
infection. (Flowers et al., 2013)
▪ Nurses play a vital role in patient and family education regarding 
the risks associated with FN. (Flowers et al., 2013)
▪ A better understanding of the etiology and prevention of FN have 
led to a reduction in morbidity over the past twenty years, with 
recognition of the importance of early administration of broad-
spectrum antibiotics. (Flowers et al., 2013)
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